Paliperidone Palmitate Injection (PP1M)
ApprovedRecruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Oct 1, 2025 → Mar 1, 2027
NCT ID
NCT07075237About Paliperidone Palmitate Injection (PP1M)
Paliperidone Palmitate Injection (PP1M) is a approved stage product being developed by Brain Biotech for Schizophrenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07075237. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07075237 | Approved | Recruiting |
Competing Products
20 competing products in Schizophrenia